Viracta Therapeutics (VIRX)
(Delayed Data from NSDQ)
$0.85 USD
+0.02 (2.61%)
Updated Apr 29, 2024 02:35 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Balance Sheet
Fiscal Year End for Viracta Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 54 | 91 | 104 | 20 | 35 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 3 | 2 | 2 | 2 |
Total Current Assets | 55 | 94 | 105 | 22 | 36 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 2 | 2 | 1 | 0 |
Total Assets | 57 | 96 | 109 | 23 | 37 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 5 |
Accounts Payable | 2 | 3 | 3 | 0 | 1 |
Current Portion Long-Term Debt | 25 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 10 | 7 | 6 | 1 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 1 | 1 |
Total Current Liabilities | 38 | 10 | 9 | 3 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 25 | 5 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 38 | 35 | 14 | 3 | 10 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 5 | 5 | 5 | 6 | 12 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 279 | 271 | 255 | 719 | 699 |
Retained Earnings | -266 | -215 | -166 | -704 | -683 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 18 | 61 | 94 | 20 | 28 |
Total Liabilities & Shareholder's Equity | 57 | 96 | 109 | 23 | 37 |
Total Common Equity | 13 | 56 | 89 | 14 | 16 |
Shares Outstanding | 38.60 | 38.20 | 37.30 | 5.10 | 3.10 |
Book Value Per Share | 0.33 | 1.46 | 2.38 | 2.82 | 5.09 |
Fiscal Year End for Viracta Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 54 | 63 | 73 | 80 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 1 | 2 | 3 |
Total Current Assets | NA | 55 | 64 | 75 | 83 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 1 | 2 | 2 |
Total Assets | NA | 57 | 66 | 77 | 86 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 2 | 3 | 2 |
Current Portion Long-Term Debt | NA | 25 | 25 | 4 | 2 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 10 | 9 | 7 | 7 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 38 | 36 | 15 | 12 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 21 | 23 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 38 | 36 | 36 | 35 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 5 | 5 | 5 | 5 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 279 | 277 | 275 | 273 |
Retained Earnings | NA | -266 | -252 | -240 | -227 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 18 | 30 | 41 | 51 |
Total Liabilities & Shareholder's Equity | NA | 57 | 66 | 77 | 86 |
Total Common Equity | 0 | 13 | 25 | 35 | 46 |
Shares Outstanding | 39.20 | 38.60 | 38.50 | 38.40 | 38.40 |
Book Value Per Share | 0.00 | 0.33 | 0.64 | 0.92 | 1.19 |